Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Office Blood Pressure (BP): Sitting diastolic blood pressure (SDBP)100-109 mmHg (inclusive) and sitting systolic blood pressure (SSBP) \< 180 mmHg after a 2 week placebo run-in period~* Home Blood Pressure: diastolic blood pressure (DBP)at home ≥ 85 mmHg in the last week of the placebo run-in period~* Normal Electrocardiogram (ECG), first degree Atrioventricular block or other changes not considered clinically significant~Exclusion Criteria:~* Secondary or severe hypertension~* History of cerebro- or cardiovascular complications~* Type 1 or Type 2 diabetes on drug treatment~* Severe renal or hepatic insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Lercanidipine 10 mg (Type: EXPERIMENTAL): None
- Lercanidipine 20 mg (Type: EXPERIMENTAL): None
- Enalapril 10 mg (Type: EXPERIMENTAL): None
- Enalapril 20 mg (Type: EXPERIMENTAL): None
- Lercanidipine 10 mg/Enalapril 10 mg (Type: EXPERIMENTAL): None
- Lercanidipine 10mg/Enalapril 20 mg (Type: EXPERIMENTAL): None
- Lercanidipine 20mg/Enalapril 10 mg (Type: EXPERIMENTAL): None
- Lercanidipine 20mg/Enalapril20mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).